# US 2020/0369676 A1 · Heterocyclic compound, application thereof and pharmaceutical composition comprising same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369676 A1
- Document ID: US20200369676A1
- Status: Published application
- Kind: A1
- Application number: 16/969,183
- Filed: 2019-02-14
- Published: 2020-11-26
- Earliest claimed: 2018-02-14
- Assignees: Suzhou Sinovent Pharmaceuticals Co., Ltd.
- Applicants: Suzhou Sinovent Pharmaceuticals Co., Ltd.
- Inventors: Yonghan HU; Dongdong WU; Wei PENG; Xin LI; Fan HU; Bin HUANG; Jinlian ZHU; Yuchuan WU
- Web page: https://patentgrep.com/patent/US20200369676A1

## CPC

- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 495/04: Ortho-condensed systems
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).

## Claims

### Claim 1

A heterocyclic compound of formula I or a pharmaceutically acceptable salt thereof, wherein,
R1 is hydrogen, cyano, halogen, C1-C4 alkyl, halogen-substituted C1-C4 alkyl, C1-C4 alkoxy, or halogen-substituted C1-C4 alkoxy;
m is 0, 1, 2, or 3, and R3 is independently selected from halogen, cyano, R3-1-substituted or unsubstituted C1-C4 alkyl, and R3-2-substituted or unsubstituted C1-C4 alkoxy; R3-1 and R3-2 are each independently selected from halogens;
W1 is ═CH— or ═N—;
W2 is ═CR4— or ═N—;
W3 is —O—, —S—, —NH—, —N═CH—, —CH═N—, or —CH═CH—;
when W2 is ═N—, R2 is hydrogen, cyano, halogen, R2-1-substituted or unsubstituted C1-C4 alkyl, —C(═O)CH3, —C(═O)CF3, —C(═O)OCH3, —C(═O)NH2, or —NHC(═O)CH3; R2-1 is independently selected from hydroxy and cyano;
when W2 is ═CR4—, one of R2 and R4 is hydrogen, cyano, halogen, R2-2-substituted or unsubstituted C1-C4 alkyl, —C(═O)CH3, —C(═O)CF3, —C(═O)OCH3, —C(═O)NH2, or —NHC(═O)CH3, and the other one is hydrogen or C1-C4 alkyl; R2-2 is independently selected from hydroxy and cyano;
R5 is halogen-substituted C1-C4 alkyl or C1-C4 alkyl;
ring A is
R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, R6-11, R6-12, R6-13, R6-14, R6-15R6-16, R6-17, and R6-18 are each independently selected from hydrogen, R6-1-1 substituted or unsubstituted C1-C4 alkyl, and C3-C6 cycloalkyl; R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each independently selected from hydrogen, cyano, halogen, C1-C4 alkyl, and halogen-substituted C1-C4 alkyl;
R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each independently selected from hydrogen, cyano, halogen, C1-C4 alkyl, and halogen-substituted C1-C4 alkyl;
R11-1 is hydrogen or halogen;
R11-2 is hydrogen, C1-C4 alkyl, or halogen-substituted C1-C4 alkyl;
ring B is a C3-C10 cycloalky, a C4-C7 cycloalkenyl, a “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, or a “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is a single bond or C1-C4 alkylene;
L2 is —O—, —C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)—CH2—, —C(═O)—C(═O)—, —C(═O)—C(═O)NRL-1—, —NRL-2—, —C(═O)NRL-3—, —NRL-4C(═O)—, —NRL-5C(O) SO2—, —SO2NRL-6—, or —NRL-7SO2—; RL-1, RL-2, RL-3, RL-4, RL-5, RL-6, and RL-7 are each independently selected from hydrogen and C1-C4 alkyl;
L3 is hydrogen, cyano, RL-8-substituted or unsubstituted C1-C4 alkyl, amino-substituted or unsubstituted C3-C7 cycloalkyl, RL-9-substituted or unsubstituted “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N and S”, RL-10-substituted or unsubstituted “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”, or, RL-11-substituted or unsubstituted“5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S”;
RL-8 is independently selected from hydroxy, cyano, halogen, and phenyl;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, C1-C4 alkyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-9-2 is independently selected from hydrogen and C1-C4 alkyl; RL-9-3 is independently selected from C1-C4 alkyl;
RL-10 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, —SO2CH3, —C(═O)RL-10-1, and —NRL-10-2(═O)RL-10-3; RL-10-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-10-2 is independently selected from hydrogen and C1-C4 alkyl; RL-10-3 is independently selected from C1-C4 alkyl;
RL-11 is independently selected from hydroxy, cyano, halogen, phenyl, —SO2CH3, —C(═O)RL-11-1, and —NRL-11-2C(═O)RL-11-3; RL-11-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-11-2 is independently selected from hydrogen and C1-C4 alkyl; RL-11-3 is independently selected from C1-C4 alkyl; and
n is 0, 1, 2, 3, or 4, R10 is independently selected from hydroxy, halogen, oxo, and R10-1-substituted or unsubstituted C1-C4 alkyl; and
R10-1 is independently selected from halogen, hydroxy, and C1-C4 alkoxy.

### Claim 2 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein, when R1 is halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R1 is halogen-substituted C1-C4 alkyl, there are one or more halogens, and in case that there are a plurality of halogens, the plurality of halogens are the same or different;
and/or, when R1 is halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine, chlorine, bromine, and iodine;
and/or, when R1 is halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, there are one or more halogens, and in case that there are a plurality of halogens, the plurality of halogens are the same or different;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, the halogen is independently selected from fluorine, chlorine, bromine, and iodine;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, the C1-C4 alkoxy is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy;
and/or, when R3 is halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R3 is R3-1-substituted C1-C4 alkyl, there are one or more R3-1, and in case that there are a plurality of R3-1, the plurality of R3-1 are the same or different;
and/or, when R3 is R3-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R3 is R3-2-substituted C1-C4 alkoxy, there are one or more R3-2, and in case that there are a plurality of R3-2, the plurality of R3-2 are the same or different;
and/or, when W2 is ═N— and R2 is halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R2 is R2-1-substituted C1-C4 alkyl, there are one or more R2-1, and in case that there are a plurality of R2-1, the plurality of R2-1 are the same or different;
and/or, when R2 is R2-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when W2 is ═CR4— and one of R2 and R4 is halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when one of R2 and R4 is R2-2-substituted C1-C4 alkyl, there are one or more R2-2, and in case that there are a plurality of R2-2, the plurality of R2-2 are the same or different;
and/or, when R5 is halogen-substituted C1-C4 alkyl, there are one or more halogens, and in case that there are a plurality of halogens, the plurality of halogens are the same or different;
and/or, when R5 is halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine, chlorine, bromine, and iodine;
and/or, when R5 is halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R5 is C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16, R6-17, and R6-18 are each independently selected from R6-1-1-substituted C1-C4 alkyl, there are one or more R6-1-1, and in case that there are a plurality of R6-1-1, the plurality of R6-1-1 are the same or different;
and/or, when R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16, R6-17, and R6-18 are each independently selected from R6-1-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-1, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16, R6-17, and R6-18 are each independently selected from C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each independently selected from halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each independently selected from halogen-substituted C1-C4 alkyl, there are one or more halogens, and in case that there are a plurality of halogens, the plurality of halogens are the same or different;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine, chlorine, bromine, and iodine;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each independently selected from halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are halogen-substituted C1-C4 alkyl, there are one or more halogens, and in case that there are a plurality of halogens, the plurality of halogens are the same or different;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine, chlorine, bromine, and iodine;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R12, R8-13, R8-14, and R8-15 are halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R11-1 is halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R11-2 is C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, there are one or more halogens, and in case that there are a plurality of halogens, the plurality of halogens are the same or different;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine, chlorine, bromine, and iodine;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when ring B is C3-C10 cycloalkyl, the C3-C10 cycloalkyl is C3-C6 cycloalkyl;
and/or, when ring B is C4-C7 cycloalkenyl, the C4-C7 cycloalkenyl is C5-C6 cycloalkenyl;
and/or, when ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is “4-7 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is linked to ring A via a carbon atom or a nitrogen atom;
and/or, when ring B is “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” is “5-6 membered heterocycloalkenyl having 1 double bond and 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when ring B is “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” is linked to ring A via a carbon atom or a nitrogen atom;
and/or, R9 is linked to a carbon atom or a nitrogen atom of ring B;
and/or, when L1 is C1-C4 alkylene, the C1-C4 alkylene is —CH2—, —CH2CH2—, —CH(CH3)—, —CH2CH2CH2—, or —CH2CH(CH3)—;
and/or, when RL-1, RL-2, RL-3, RL-4, RL-5, RL-6, and RL-7 are each independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when L3 is RL-8-substituted C1-C4 alkyl, there are one or more RL-8, and in case that there are a plurality of RL-8, the plurality of RL-8 are the same or different;
and/or, when L3 is RL-8 substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when L3 is amino-substituted C3-C7 cycloalkyl, there are one or more aminos;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-9 there are one or more RL-9, and in case that there are a plurality of RL-9, the plurality of RL-9 are the same or different;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-9, RL-9 is linked to a carbon atom or a nitrogen atom of the heterocycloalkyl;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9, the “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is “4-10 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9, the heterocycloalkyl is linked to L2 via a carbon atom or a nitrogen atom;
and/or, when RL-9 is halogen, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when RL-9 is independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when RL-9 is independently selected from hydroxy-substituted C1-C4 alkyl, there are one or more hydroxys;
and/or, when RL-9 is independently selected from hydroxy-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when L3 is “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-10, there are one or more RL-10, and in case that there are a plurality of RL-10, the plurality of RL-10 are the same or different;
and/or, when L3 is “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-10, RL-10 is linked to a carbon atom or a nitrogen atom of the heterocycloalkenyl;
and/or, when L3 is “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-10, the “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” is “5-6 membered heterocycloalkenyl having 1 double bond and 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when L3 is “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-10, the heterocycloalkenyl is linked to L2 via a carbon atom or a nitrogen atom;
and/or, when L3 is “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-11, there are one or more RL-11, and in case that there are a plurality of RL-11, the plurality of RL-11 are the same or different;
and/or, when L3 is “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-11, the “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S” is “5-6 membered heteroaryl having 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when L3 is “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-11, the “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S” is linked to L via a carbon atom or a nitrogen atom;
and/or, when R10 is independently selected from halogens, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, when R10 is independently selected from R10-1-substituted C1-C4 alkyl, there are one or more R10-1, and in case that there are a plurality of R10-1, the plurality of R10-1 are the same or different;
and/or, when R10 is independently selected from R10-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
and/or, when R10-1 is independently selected from halogens, the halogen is fluorine, chlorine, bromine, or iodine;
and/or, R10 is independently located at the ortho, meta or para position relative to ring A;
and/or, R10 is linked to a carbon atom or a nitrogen atom of ring B.

### Claim 3 (depends on 2)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 2, wherein, when R1 is halogen, the halogen is fluorine;
and/or, when R1 is halogen-substituted C1-C4 alkyl, there are one or two halogens;
and/or, when R1 is halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine;
and/or, when R1 is halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, there are one or two halogens;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, the halogen is independently selected from fluorine;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, the C1-C4 alkoxy is methoxy or ethoxy;
and/or, when R3 is halogen, the halogen is fluorine;
and/or, when R3 is R3-1-substituted or -unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when W2 is ═N— and R2 is halogen, the halogen is fluorine;
and/or, when R2 is R2-1-substituted or -unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when W2 is ═CR4—, and one of R2 and R4 is halogen, the halogen is fluorine;
and/or, when R5 is halogen-substituted C1-C4 alkyl, there are one or two halogens;
and/or, when R5 is halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine;
and/or, when R5 is halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when R5 is C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16, R6-17, and R6-18 are each independently selected from R6-1-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl, ethyl, or isopropyl;
and/or, when R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16, R6-17, and R6-18 are each independently selected from C3-C6 cycloalkyl, the C3-C6 cycloalkyl is cyclopropyl;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each independently selected from halogens, the halogen is fluorine;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each halogen-substituted C1-C4 alkyl, there are one or two halogens;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each independently selected from halogens, the halogen is fluorine;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each halogen-substituted C1-C4 alkyl, there are one or two halogens;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when R1 is halogen, the halogen is fluorine;
and/or, when R11-2 is C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, there are one or two halogens;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, the halogen is independently selected from fluorine;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when ring B is C3-C10 cycloalkyl, the C3-C10 cycloalkyl is C5-C6 cycloalkyl;
and/or, when ring B is C4-C7 cycloalkenyl, the C4-C7 cycloalkenyl is cyclohexenyl;
and/or, when ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is “5-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is linked to ring A via a nitrogen atom;
and/or, when ring B is “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” is
and/or, R9 is linked to a nitrogen atom of ring B;
and/or, when L1 is C1-C4 alkylene, the C1-C4 alkylene is —CH2—;
and/or, when RL-1, RL-2, RL-3, RL-4, RL-5, RL-6, and RL-7 are each independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when L3 is RL-8-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when L3 is “4-10 membered monocyclic, bicyclic or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-9 there are one or more RL-9, such as 2, 3, or 4 RL-9;
and/or, when L3 is “4-10 membered monocyclic, bicyclic or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-9 and RL-9 is linked to a carbon atom in the heterocycloalkyl, the carbon atom in the heterocycloalkyl, linked to RL-9, is independently in R or S configuration;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N and S” which is substituted or unsubstituted with RL-9, the “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is “4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S”;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9, the heterocycloalkyl is linked to L2 via a nitrogen atom;
and/or, when RL-9 is independently selected from halogens, the halogen is fluorine;
and/or, when RL-9 is independently selected from C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when RL-9 is independently selected from hydroxy-substituted C1-C4 alkyl, the hydroxy-substituted C1-C4 alkyl is hydroxymethyl;
and/or, when L3 is “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-10, and RL-10 is linked to a carbon atom in the heterocycloalkenyl, the carbon in the heterocycloalkenyl, linked to RL-10, is independently in R configuration or S configuration;
and/or, when L3 is “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-10, the heterocycloalkenyl is linked to L2 via a nitrogen atom;
and/or, when L3 is “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-11, the “5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N and S” is linked to L2 via a nitrogen atom;
and/or, when R10 is independently selected from halogens, the halogen is fluorine;
and/or, when R10 is independently selected from R10-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl;
and/or, when R10-1 is independently selected from halogens, the halogen is fluorine;
and/or, R1 is linked to a carbon atom in ring B.

### Claim 4 (depends on 3)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 3, wherein, when R1 is halogen-substituted C1-C4 alkyl, the “halogen-substituted C1-C4 alkyl” is 2-fluoroethyl, 2,2-difluoroethyl, or 2,2,2-trifluoroethyl;
and/or, when R1 is halogen-substituted C1-C4 alkoxy, the “halogen-substituted C1-C4 alkoxy” is 2-fluoroethoxy, 2,2-difluoroethoxy, or 2,2,2-trifluoroethoxy;
and/or, when R5 is halogen-substituted C1-C4 alkyl, the “halogen-substituted C1-C4 alkyl” is 2-fluoroethyl, 2,2-difluoroethyl, or 2,2,2-trifluoroethyl;
and/or, when R5 is C1-C4 alkyl, the C1-C4 alkyl is ethyl;
and/or, when R6-1R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16, R6-17, and R6-18 are each independently selected from R6-1-1-substituted or unsubstituted C1-C4 alkyl, the C1-C4 alkyl is methyl or ethyl;
and/or, when R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, R7-10, and R7-11 are each halogen-substituted C1-C4 alkyl, the “halogen-substituted C1-C4 alkyl” is 2-fluoroethyl, 2,2-difluoroethyl, or 2,2,2-trifluoroethyl;
and/or, when R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13, R8-14, and R8-15 are each halogen-substituted C1-C4 alkyl, the “halogen-substituted C1-C4 alkyl” is 2-fluoroethyl, 2,2-difluoroethyl, or 2,2,2-trifluoroethyl;
and/or, when R11-2 is halogen-substituted C1-C4 alkyl, the “halogen-substituted C1-C4 alkyl” is 2-fluoroethyl, 2,2-difluoroethyl, or 2,2,2-trifluoroethyl;
and/or, when ring B is C4-C7 cycloalkenyl, the C4-C7 cycloalkenyl is
and/or, when ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is
wherein X is N or CH, Y is NH or CH2, but X and Y are not both carbon;
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9, the “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is

### Claim 5 (depends on 4)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 4, wherein, when ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, the “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” is
and/or, when L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9, the “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted with RL-9 is

### Claim 6 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein any of the following schemes is adopted:
scheme 1: ring A is
R6-1 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-1 is hydrogen, halogen, or C1-C4 alkyl; and R8-1 is hydrogen;
scheme 2: ring A is
R6-3 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-3 is hydrogen, halogen, or C1-C4 alkyl; and R8-6 is hydrogen;
scheme 3: ring A is
R6-6 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-4 is hydrogen, halogen, or C1-C4 alkyl; and R8-6 is hydrogen;
scheme 4: ring A is
R6-10 is C1-C4 alkyl or C3-C6 cycloalkyl; and R8-9 is hydrogen;
scheme 5: ring A is
R6-7 is C1-C4 alkyl or C3-C6 cycloalkyl; and R8-7 is hydrogen;
scheme 6: ring A is
R6-14 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-7 is hydrogen, halogen, or C1-C4 alkyl; and R8-12 is hydrogen;
scheme 7: ring A is
R6-18 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-11 is hydrogen, halogen, or C1-C4 alkyl; and R8-15 is hydrogen;
scheme 8: ring A is
R6-16 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-9 is hydrogen, halogen, or C1-C4 alkyl; and R8-13 is hydrogen;
scheme 9: ring A is
R6-17 is C1-C4 alkyl or C3-C6 cycloalkyl; R7-10 is hydrogen, halogen, or C1-C4 alkyl; R8-14 is hydrogen; and R11-2 is hydrogen or C1-C4 alkyl.

### Claim 7 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R1 is halogen, halogen-substituted C1-C4 alkyl, or halogen-substituted C1-C4 alkoxy;
and/or, m is 0 or 1, and R3 is halogen;
and/or, W1 is ═N—;
and/or, W2 is ═CR4—;
and/or, when W2 is ═CR4—, one of R2 and R4 is hydrogen or cyano, and the other is hydrogen;
and/or, W3 is —O—, —S—, or —NH—;
and/or, R5 is methyl, ethyl, 2-fluoroethyl, or 2,2-difluoroethyl;
and/or, ring A is
R6-1, R6-3, R6-6, R6-7, R6-10, R6-14, R6-16, R6-17, and R6-18 are each independently selected from C1-C4 alkyl and C3-C6 cycloalkyl; R7-1, R7-3, R7-4, R7-7, R7-9, R7-10 and R7-11 are each independently selected from hydrogen, halogen, C1-C4 alkyl, and halogen-substituted C1-C4 alkyl; R8-1, R8-3, R8-6, R8-7, R8-9, R8-12, R8-13, R8-14 and R8-15 are each independently selected from hydrogen and halogen-substituted C1-C4 alkyl; and R11-2 is hydrogen, C1-C4 alkyl, or halogen-substituted C1-C4 alkyl;
and/or, ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”; n is 0 or 1, R10 is oxo or R10-1-substituted or unsubstituted C1-C4 alkyl, and R10-1 is independently selected from halogens;
and/or, L1 is C1-C4 alkylene;
and/or, L2 is —C(═O)—, —C(═O)—CH2—, —C(═O)—C(═O)—, or —SO2—;
and/or, L3 is RL-8 substituted or unsubstituted C1-C4 alkyl, or “4-10 membered monocyclic, bicyclic or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9; RL-8 is independently selected from hydroxy, and RL-9 is independently selected from hydroxy and C1-C4 alkyl.

### Claim 8 (depends on 7)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 7, wherein, R1 is halogen;
and/or, when W2 is ═CR4—, one of R2 and R4 is cyano and the other is hydrogen;
and/or, W3 is —S—;
and/or, R5 is ethyl, 2-fluoroethyl, or 2,2-difluoroethyl;
and/or, ring A is
R6-1, R6-3, R6-6, R6-7, R6-10, R6-14, R6-16, R6-17, and R6-18 are each independently selected from C1-C4 alkyl and C3-C6 cycloalkyl; R7-1, R7-3, R7-4, R7-7, R7-9, R7-10, and R7-11 are each independently selected from hydrogen, fluorine, C1-C4 alkyl, and halogen-substituted C1-C4 alkyl; R8-1, R8-3, R8-6, R8-7, R8-9, R8-12, R8-13, R8-14 and R8-15 are each independently selected from hydrogen and halogen-substituted C1-C4 alkyl; and R11-2 is hydrogen, C1-C4 alkyl, or halogen-substituted C1-C4 alkyl;
and/or, ring B is “4-7 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S”; n is 0 or 1, R10 is R10-1-substituted or unsubstituted C1-C4 alkyl, and R10-1 is independently selected from halogens;
and/or, L2 is —C(═O)—;
and/or, L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9; RL-9 is independently selected from hydroxy and C1-C4 alkyl.

### Claim 9 (depends on 8)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 8, wherein, when W2 is ═CR4—, R2 is hydrogen, and R4 is cyano;
and/or, ring A is
R6-1, R6-3, R6-7, R6-14, R6-16, and R6-17 are each independently selected from C1-C4 alkyl and C3-C6 cycloalkyl; R7-1, R7-3, R7-7, R7-9, and R7-10 are each independently selected from hydrogen, fluorine, and C1-C4 alkyl; and R8-1, R8-3, R8-7, R8-12, R8-13, and R8-14 are each independently selected from hydrogen;
and/or, L3 is “4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9; RL-9 is independently selected from hydroxy and C1-C4 alkyl.

### Claim 10 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R1 is halogen, halogen-substituted C1-C4 alkyl, or halogen-substituted C1-C4 alkoxy;
m is 0 or 1, and R3 is halogen;
W1 is ═N—;
W2 is ═CR4—;
W3 is —O—, —S—, or —NH—;
when W2 is ═CR4—, one of R2 and R4 is cyano, and the other is hydrogen;
R5 is halogen-substituted C1-C4 alkyl or C1-C4 alkyl;
ring A is
R6-1, R6-3, R6-6, R6-7, R6-10, R6-14, R6-16, R6-17, and R6-18 are each independently selected from C1-C4 alkyl and C3-C6 cycloalkyl;
R7-1, R7-3, R7-4, R7-7, R7-9, R7-10 and R7-11 are each independently selected from hydrogen, fluorine, C1-C4 alkyl, and halogen-substituted C1-C4 alkyl;
R8-1, R8-3, R8-6, R8-7, R8-9, R8-12, R8-13, R8-14, and R8-15 are each independently selected from hydrogen and halogen-substituted C1-C4 alkyl;
R11-2 is hydrogen, C1-C4 alkyl, or halogen-substituted C1-C4 alkyl;
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from hydroxy and C1-C4 alkyl; and
n is 0 or 1, R10 is R10-1-substituted or unsubstituted C1-C4 alkyl, and R10-1 is independently selected from halogens.

### Claim 11 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R1 is halogen;
m is 0 or 1, and R3 is halogen;
W1 is ═N—;
W2 is ═CR4—;
W3 is —O—, —S—, or —NH—;
when W2 is ═CR4—, one of R2 and R4 is cyano, and the other is hydrogen;
R5 is methyl, ethyl, 2-fluoroethyl, or 2,2-difluoroethyl;
ring A is
R6-3, R6-7, R6-14, R6-16, and R6-17 are each independently selected from C1-C4 alkyl and C3-C6 cycloalkyl;
R7-3, R7-7, R7-9, and R7-10 are each independently selected from hydrogen, fluorine, and C1-C4 alkyl;
R8-3, R8-7, R8-12, R8-13, and R8-14 are each independently selected from hydrogen;
ring B is “4-7 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-6 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from hydroxy and C1-C4 alkyl; and
n is 0 or 1, R10 is R10-1-substituted or unsubstituted C1-C4 alkyl, and R10-1 is independently selected from halogens.

### Claim 12 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R1 is hydrogen, cyano, halogen, C1-C4 alkyl, or C1-C4 alkoxy;
m is 0, 1, 2, or 3, and R3 is independently selected from halogen, cyano, R3-1-substituted or unsubstituted C1-C4 alkyl, and R3-2-substituted or unsubstituted C1-C4 alkoxy; R3-1 and R3-2 are each independently selected from halogens;
W1 is ═CH— or ═N—;
W2 is ═CR4— or ═N—;
W3 is —O—, —S—, —NH—, —N═CH—, —CH═N—, or —CH═CH—;
when W2 is ═N—, R2 is hydrogen, cyano, halogen, R2-1-substituted or unsubstituted C1-C4 alkyl, —C(═O)CH3, —C(═O)CF3, —C(═O)OCH3, —C(═O)NH2, or —NHC(═O)CH3; R2-1 is independently selected from hydroxy and cyano;
when W2 is ═CR4—, one of R2 and R4 is hydrogen, cyano, halogen, R2-2-substituted or unsubstituted C1-C4 alkyl, —C(═O)CH3, —C(═O)CF3, —C(═O)OCH3, —C(═O)NH2, or —NHC(═O)CH3, and the other one is hydrogen or C1-C4 alkyl; R2-2 is independently selected from hydroxy and cyano;
R5 is C1-C4 alkyl;
ring A is
R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R8-7, R6-8, R6-9, R6-1, R6-11, R6-12, R6-13, R6-14, R6-15, R6-16 and R6-17 are each independently selected from hydrogen and R6-11-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1, R7-2, R7-3, R7-4, R7-5, R7-6, R7-7, R7-8, R7-9, and R7-10 are each independently selected from hydrogen, cyano, halogen, and C1-C4 alkyl;
R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, R8-9, R8-10, R8-11, R8-12, R8-13 and R8-14 are each independently selected from hydrogen, cyano, halogen, and C1-C4 alkyl;
R1 is hydrogen or halogen;
ring B is a C3-C10 cycloalky, a C4-C7 cycloalkenyl, a “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, or a “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is a single bond or C1-C4 alkylene;
L2 is —O—, —C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)—C(═O)—, —C(═O)—C(═O)NRL-1— —NRL-2—, —C(═O)NRL-3—, —NRL-4C(═O)—, —NRL-5C(═O)O—, —SO2—, —SO2NRL-6—, or —NRL-7SO2—; RL-1, RL-2, RL-3, RL-4, RL-5, RL-6, and RL-7 are each independently selected from hydrogen and C1-C4 alkyl;
L3 is hydrogen, cyano, RL-8-substituted or unsubstituted C1-C4 alkyl, amino-substituted or unsubstituted C3-C7 cycloalkyl, RL-9-substituted or unsubstituted “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N and S”, RL-10-substituted or unsubstituted “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”, or, RL-1-substituted or unsubstituted“5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S”;
RL-8 is independently selected from hydroxy, cyano, halogen, and phenyl;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl;
RL-10 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, —SO2CH3, —C(═O)RL-10-1, and —NRL-10-2(═O)RL-10-3; RL-10-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-10-2 is independently selected from hydrogen and C1-C4 alkyl; RL-10-3 is independently selected from C1-C4 alkyl;
RL-10 is independently selected from hydroxy, cyano, halogen, phenyl, —SO2CH3, —C(═O)RL-11-1, and —NRL-11-2C(═O)RL-11-3; RL-11-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-11-2 is independently selected from hydrogen and C1-C4 alkyl; RL-11-3 is independently selected from C1-C4 alkyl; and
n is 0, 1, 2, 3, or 4, R10 is independently selected from hydroxy, halogen, oxo, and R10-1-substituted or unsubstituted C1-C4 alkyl; R10-1 is independently selected from hydroxy and C1-C4 alkoxy.

### Claim 13 (depends on 12)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 12, wherein any of the following schemes is adopted:
scheme A: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-7 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R8-7 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and n is 0;
scheme B: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-1 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1 is halogen;
R8-1 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and n is 0;
scheme C: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-1 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1 is fluorine;
R8-1 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1—, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0;
scheme D: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-6 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-4 is hydrogen or halogen;
R8-6 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0;
scheme E: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-10 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R8-9 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0;
scheme F: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-3 is R6-1-1 substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-3 is hydrogen, fluorine, or C1-C4 alkyl;
R8-3 is hydrogen or fluorine;
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0;
scheme G: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-8 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-5 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0;
scheme H: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-9 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R8-8 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0;
scheme J: R1 is cyano or halogen;
m is 1;
R3 is cyano or halogen;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is —S—;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-1 is R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1 is halogen;
R8-1 is hydrogen; and
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0.

### Claim 14 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein, any of the following schemes is adopted:
scheme I: R1 is hydrogen, cyano, halogen, or C1-C4 alkyl;
m is 0, 1, 2, or 3, and R3 is independently selected from halogen, cyano, R3-1-substituted or unsubstituted C1-C4 alkyl, and R3-2-substituted or unsubstituted C1-C4 alkoxy; R3-1 and R3-2 are each independently selected from halogens;
W1 is ═CH— or ═N—;
W2 is ═CR4— or ═N—;
W3 is —O—, —S—, —NH—, —N═CH—, —CH═N—, or —CH═CH—;
when W2 is ═N—, R2 is hydrogen, cyano, halogen, R2-1-substituted or unsubstituted C1-C4 alkyl, —C(═O)CH3, —C(═O)CF3, —C(═O)OCH3, —C(═O)NH2, or —NHC(═O)CH3; R2-1 is independently selected from hydroxy and cyano;
when W2 is ═CR4—, one of R2 and R4 is hydrogen, cyano, halogen, R2-2-substituted or unsubstituted C1-C4 alkyl, —C(═O)CH3, —C(═O)CF3, —C(═O)OCH3, —C(═O)NH2, or —NHC(═O)CH3, and the other one is hydrogen or C1-C4 alkyl; R2-2 is independently selected from hydroxy and cyano;
R5 is C1-C4 alkyl;
ring A is
R6-1, R6-2, R6-3, R6-4, R6-5, R6-6, R6-7, R6-8, R6-9, R6-10, and R6-11 are each independently selected from hydrogen and R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R61 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1, R7-2, R7-3, R7-4, R7-5, and R7-6 are each independently selected from hydrogen, cyano, halogen, and C1-C4 alkyl; and
R8-1, R8-2, R8-3, R8-4, R8-5, R8-6, R8-7, R8-8, and R8-9 are each independently selected from hydrogen, cyano, halogen, and C1-C4 alkyl;
ring B is a C3-C10 cycloalky, a C4-C7 cycloalkenyl, a “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”, or a “4-7 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is a single bond or C1-C4 alkylene;
L2 is —O—, —C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)—C(═O)—, —C(═O)—C(═O)NRL-1—, —NRL-2—, —C(═O)NRL-3—, —NRL-4C(═O)—, —NRL-5C(═O)O—, —SO2—, —SO2NRL-6—, or —NRL-7SO2—; RL-1, RL-2, RL-3, RL-4, RL-5, RL-6, and RL-7 are each independently selected from hydrogen and C1-C4 alkyl;
L3 is hydrogen, cyano, RL-8-substituted or unsubstituted C1-C4 alkyl, amino-substituted or unsubstituted C3-C7 cycloalkyl, RL-9-substituted or unsubstituted “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N and S”, RL-10-substituted or unsubstituted “5-6 membered heterocycloalkenyl having 1 double bond and 1-3 heteroatoms selected from one or more of O, N, and S”, or, RL-H substituted or unsubstituted“5-6 membered heteroaryl having 1-3 heteroatoms selected from one or more of O, N, and S”;
RL-8 is independently selected from hydroxy, cyano, halogen, and phenyl;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1, and —NRL-9-2C(═O)RL-9-3; RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl;
RL-10 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, —SO2CH3, —C(═O)RL-10-1, and —NRL-10-2(═O)RL-10-3; RL-10-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-10-2 is independently selected from hydrogen and C1-C4 alkyl; RL-10-3 is independently selected from C1-C4 alkyl;
RL-11 is independently selected from hydroxy, cyano, halogen, phenyl, —SO2CH3, —C(═O)RL-11-1, and —NRL-11-2C(═O)RL-11-3; RL-11-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy; RL-11-2 is independently selected from hydrogen and C1-C4 alkyl; RL-11-3 is independently selected from C1-C4 alkyl; and
n is 0, 1, 2, 3, or 4, R10 is independently selected from hydroxy, halogen, oxo, and R10-1-substituted or unsubstituted C1-C4 alkyl; R10-1 is independently selected from hydroxy and C1-C4 alkoxy;
scheme II: R1 is cyano or halogen;
m is 0;
W1 is ═N—;
W2 is ═CR4— or ═N—;
W3 is -5-;
when W2 is ═N—, R2 is hydrogen, cyano, or methyl;
when W2 is ═CR4—, “R4 is cyano and R2 is hydrogen”, or, “R4 is hydrogen and R2 is cyano”;
R5 is C1-C4 alkyl;
ring A is
R6-1 and R6-7 are each independently selected from R6-1-1-substituted or unsubstituted C1-C4 alkyl, and R6-1-1 is independently selected from hydroxy, cyano, halogen, and —C(═O)NH2;
R7-1 is halogen;
R8-1 and R1-7 are hydrogen;
ring B is “4-10 membered monocyclic or bicyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S”;
R9 is -L1-L2-L3;
L1 is C1-C4 alkylene;
L2 is —C(═O)—;
L3 is “4-10 membered monocyclic, bicyclic, or spirocyclic heterocycloalkyl having 1-3 heteroatoms selected from one or more of O, N, and S” which is substituted or unsubstituted with RL-9;
RL-9 is independently selected from oxo, hydroxy, cyano, halogen, phenyl, hydroxy-substituted C1-C4 alkyl, —SO2CH3, —C(═O)RL-9-1 and —NRL-9-2C(═O)RL-9-3, RL-9-1 is independently selected from C1-C4 alkyl and C1-C4 alkoxy, RL-9-2 is independently selected from hydrogen and C1-C4 alkyl, and RL-9-3 is independently selected from C1-C4 alkyl; and
n is 0.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, wherein the heterocyclic compound of formula I is any one of the following compounds:
S-0021: 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)imidazo [1,2-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0058: 2-(ethyl(2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl) imidazo[1,2-a]pyrimidin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0025: 2-((2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0027: 4-(3,4-difluorophenyl)-2-((2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)thiazole-5-carbonitrile;
S-0122: 2-(ethyl(2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-indazol-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0123: 4-(3,4-difluorophenyl)-2-(ethyl(2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-indazol-3-yl)amino)thiazole-5-carbonitrile;
S-0125: 2-((7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2-isopropyl-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0126: 2-((2-cyclopropyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl) piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0131: 2-((2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-2-(trifluoromethyl)piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0134: 2-(ethyl(2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-2-(trifluoromethyl)piperazin-1-yl)-2H-indazol-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0029: 2-(4-(2-ethyl-7-fluoro-3-((3-(4-fluorophenyl)-1,2,4-thiadiazol-5-yl)(methyl) amino)-2H-indazol-5-yl)piperazin-1-yl)-1-(3-hydroxyazetidin-1-yl)ethyl-1-one,
S-0030: 6-((2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)-2-(4-fluorophenyl)nicotinonitrile;
S-0080: 2-(4-(2-ethyl-7-fluoro-3-((4-(4-fluorophenyl)pyrimidin-2-yl)(methyl)amino)-2H-indazol-5-yl)piperazin-1-yl)-1-(3-hydroxyazetidin-1-yl)ethyl-1-one,
S-0135: 2-(ethyl(2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-3-(trifluoromethyl)piperazin-1-yl)-2H-indazol-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0022: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methyl-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-103: 2-((7-chloro-2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0094: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-pyrazolo[4,3-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0117: 2-(ethyl(2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-pyrazolo[4,3-b]pyridin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0095: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methyl-2H-pyrazolo[4,3-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0124: 2-(ethyl(2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methyl-2H-pyrazolo[4,3-b]pyridin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0140: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methyl-2H-pyrazolo[4,3-b]pyridin-3-yl)(2,2,2-trifluoroethyl)amino)-4-(4-fluorophenyl) thiazole-5-carbonitrile;
S-0141: 2-((2,2-difluoroethyl)(2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl) piperazin-1-yl)-7-methyl-2H-pyrazolo[4,3-b]pyridin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0144: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methyl-2H-pyrazolo[4,3-b]pyridin-3-yl)(2-fluoroethyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0043: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-pyrazolo[3,4-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0044: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-2H-pyrazolo[3,4-c]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0024: 2-((2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)benzofuran-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0045: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)furo [2,3-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0097: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)furo [3,2-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0105CP: 2-(ethyl(2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl) furo[3,2-b]pyridin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0046: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)furo [2,3-c]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0098: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-1H-pyrrolo[3,2-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0128: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile,
S-0129: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)thieno [3,2-b]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0035: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile,
S-0068: 4-(3,4-difluorophenyl)-2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl) piperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)thiazole-5-carbonitrile,
S-0069: 2-(ethyl(2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazine-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile,
S-0070: (R)-2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-2-methylpiperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0071: (S)-2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-2-methylpiperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0074: (R)-2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-3-methylpiperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0075: (S)-2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-3-methylpiperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile
S-0099: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoacetyl)piperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0100CP: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)acetyl)piperazin-1-yl)-7-methylpyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0041: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrazolo [1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0082: 2-(ethyl(2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl) pyrazolo[1,5-a]pyrimidin-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0104CP: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-3-oxopiperazin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0120: 2-((2-ethyl-5-(4-(2-(3-hydroxy-3-methylazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0121: 4-(3,4-difluorophenyl)-2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl) piperazin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)thiazole-5-carbonitrile;
S-0102CP: 2-((2-ethyl-5-(4-(2-hydroxyethylsulfonyl)piperazin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0103CP: 2-((2-ethyl-5-(4-(ethylsulfonyl)piperazin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl) (methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0040: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)pyrazolo [1,5-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0023: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-7-methylbenzofuran-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;
S-0149: 2-(4-(2-ethyl-3-(ethyl(4-(4-fluorophenyl)thiazol-2-yl)amino)-7-fluoro-2H-indazol-5-yl)piperazin-1-yl)-1-(3-hydroxyazetidin-1-yl)ethanone,
S-0151: 2-(4-(2-ethyl-3-(ethyl(4-(4-fluorophenyl)thiazol-2-yl)amino)-7-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)piperazin-1-yl)-1-(3-hydroxyazetidin-1-yl)ethanone,
2-((2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-2-(trifluoromethyl)piperazin-1-yl)-2H-indazol-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile having a retention time of 3.87 min or 5.09 min under the following analytical conditions: column: AD-H, 4.6*100 mm, 5 μm; mobile phase: ethanol (containing 1% of a solution of ammonia in methanol);
2-(ethyl(2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-2-(trifluoromethyl)piperazin-1-yl)-2H-indazol-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile having a retention time of 3.05 min or 4.26 min under the following analytical conditions: column: AD-H, 4.6*100 mm, 5 μm; mobile phase: ethanol (containing 1% of a solution of ammonia in methanol); and
2-(ethyl(2-ethyl-7-fluoro-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-3-(trifluoromethyl)piperazin-1-yl)-2H-indazol-3-yl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile having a retention time of 10.04 min or 11.09 min under the following analytical conditions: column: OD-H, 4.6*250 mm, 5 μm; mobile phase: hexane (containing 0.1% diethanolamine): ethanol (containing 0.1% diethanolamine)=80:20.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method for inhibiting Autotaxin, preventing and/or treating “diseases associated with Autotaxin”, or preventing and/or treating “one or more of a fibrotic disease, a proliferative disease, an inflammatory disease, an autoimmune disease, a respiratory disease, a cardiovascular disease, a neurodegenerative disease, a dermatological disease, and a disease associated with abnormal angiogenesis” in a subject in need thereof, comprising: administering an effective amount of the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.

### Claim 19 (depends on 1)

A pharmaceutical composition, comprising the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutical excipient.

### Claim 20 (depends on 1)

A method for preventing and/or treating diseases associated with Autotaxin in a subject in need thereof, comprising: administering an effective amount of the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1 to the subject, wherein the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof is used in combination with another therapeutic agent.

### Claim 21 (depends on 1)

A method for preventing and/or treating diseases associated with Autotaxin in a subject in need thereof, comprising: administering an effective amount of nintedanib or a pharmaceutically acceptable salt thereof to the subject,
wherein, the nintedanib or the pharmaceutically acceptable salt thereof is used in combination with the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1;
or,
the nintedanib or the pharmaceutically acceptable salt thereof is used in combination with a substance B, and the substance B refers to “the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, and pirfenidone or a pharmaceutically acceptable salt thereof”.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method for preventing and/or treating diseases associated with Autotaxin in a subject in need thereof, comprising: administering an effective amount of pirfenidone or a pharmaceutically acceptable salt thereof to the subject,
wherein, the pirfenidone or the pharmaceutically acceptable salt thereof is used in combination with the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1;
or,
the pirfenidone or the pharmaceutically acceptable salt thereof is used in combination with a substance C, and the substance C refers to “the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, and nintedanib or a pharmaceutically acceptable salt thereof”.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A combination, comprising the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, and another therapeutic agent.

### Claim 26 (depends on 25)

A pharmaceutical composition, comprising the combination according to claim 25 and a pharmaceutical excipient.

### Claim 27 (depends on 1)

A combination kit comprising a pharmaceutical composition A and a pharmaceutical composition X, wherein
the pharmaceutical composition A comprises the heterocyclic compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutical excipient;
the pharmaceutical composition X refers to a pharmaceutical composition B or a pharmaceutical composition C;
the pharmaceutical composition B comprises nintedanib or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient; and
the pharmaceutical composition C comprises pirfenidone or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient.
